The Joint Role of Serum Markers of Congestion or Myocardial Necrosis And Speckle Tracking Echocardiography in The Detection of Early Subtle Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer

Aim     To monitor the dynamics of biomarkers during chemotherapy, targeted chemotherapy and targeted monotherapy in patients with HER2-positive breast cancer (BC); to analyze the emergence timing of these changes; to compare early biochemical and echocardiographic criteria; and to determine the best time for assessing latent subclinical cardiac dysfunction.

Material and methods            Patients with BC (229 women aged 57±11 years) treated sequentially with anthracyclines, a combination of docetaxel and trastuzumab, and trastuzumab monotherapy were examined during three blocks of BC therapy until the development of clinical cardiotoxicity. Time-related changes in high-sensitivity cardiac troponin I, N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular (LV) global longitudinal strain (GLS) and LV ejection fraction (EF) (up to 12 speckle-tracking echocardiograms/up to 12 laboratory tests) were analyzed. Clinical cardiotoxicity was defined as a symptomatic decrease in LV EF ≥10% from the baseline value of 54% or more.

Results            Clinically significant cardiotoxicity developed in 6.3-10.9% of cases depending on the treatment option for BC. Early manifestations of cardiotoxicity were detected already at 3 weeks after the start of the first course of chemotherapy. For the BC treatment with anthracyclines and targeted chemotherapy with docetaxel and trastuzumab, the markers of clinical cardiotoxicity were high-sensitivity cardiac troponin I, NT-proBNP and GLS LV. For the trastuzumab monotherapy, only GLS LV had a prognostic value. No statistically significant changes in the concentrations of high-sensitivity troponin I and NT-proBNP were found.

Conclusion      For timely detection of clinical cardiotoxicity, laboratory tests (high-sensitivity troponin I, NT-proBNP) and echocardiography (GLS LV) are recommended to be performed every 3 weeks before the next course of BC therapy. While doing so, their sensitivity will depend on the treatment option for BC.

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229–63. DOI: 10.3322/caac.21834

2. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G. Cardio-oncology: A new medical issue. Ecancermedicalscience. 2008;2:126. DOI: 10.3332/ecancer.2008.126

3. Belenkov Yu.N., Ilgisonis I.S., Kirichenko Yu.Yu., Murtuzaliev Sh.M. Cardio-oncology today: digest of the first European clinical guidelines (2022). Kardiologiia. 2023;63(7):3–15. DOI: 10.18087/cardio.2023.7.n2445

4. Vitsenya M.V., Ageev F.T., Orlova R.V., Poltavskaya M.G., Potievskaya V.I. Cardiovascular toxicity. RUSSCO practical recommendations, part 2. Malignant tumors. 2024;14(3s2):97–121. DOI: 10.18027/2224-5057-2024-14-3s2-2-06

5. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal. 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244

6. Practical recommendations for the drug treatment of malignant tumors. Practical recommendations for supportive therapy in oncology. Edited by V.M. Moiseenko. - M.: All-Russian public organization ‘Russian Society of Clinical Oncology’; 2015. - 456p. ISBN 978-5-9903154-5-7

7. Akbalaeva B.A., Shulzhenko L.V., Pershukov I.V., Raiimbek uulu N., Batyraliev T.A., Gurovich O.V. et al. Speckle-Tracking Echocardiography in Assessment of Breast Cancer Therapy-Related Subclinical Cardiac Dysfunction. Innovative Medicine of Kuban. 2024;9(2):8–15. DOI: 10.35401/2541-9897-2024-9-2-8-15

8. Pershukov I.V., Akbalaeva B.A., Shulzhenko L.V., Batyraliev T.A., Gurovich O.V., Vinogradskaya V.V. et al. Echo-loop of subclinical cardiovascular toxicity in women associated with HER2-positive breast cancer therapy. Cardiovascular Therapy and Prevention. 2024;23(6):57– 65. DOI: 10.15829/1728-8800-2024-4038

9. Sulaiman L, Hesham D, Abdel Hamid M, Youssef G. The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients. The Egyptian Heart Journal. 2021;73(1):20. DOI: 10.1186/s43044-021-00142-z

10. Tlegenova Zh, Balmagambetova S, Zholdin B, Kurmanalina G, Talipova I, Koyshybaev A et al. Role of Clinical Risk Factors and B-Type Natriuretic Peptide in Assessing the Risk of Asymptomatic Cardiotoxicity in Breast Cancer Patients in Kazakhstan. Diagnostics. 2023;13(23):3557. DOI: 10.3390/diagnostics13233557

11. Bhagat AA, Kalogeropoulos AP, Baer L, Lacey M, Kort S, Skopicki HA et al. Biomarkers and Strain Echocardiography for the Detection of Subclinical Cardiotoxicity in Breast Cancer Patients Receiving Anthracyclines. Journal of Personalized Medicine. 2023;13(12):1710. DOI: 10.3390/jpm13121710

12. Thavendiranathan P, Negishi T, Coté M-A, Penicka M, Massey R, Cho G-Y et al. Single Versus Standard Multiview Assessment of Global Longitudinal Strain for the Diagnosis of Cardiotoxicity During Cancer Therapy. JACC: Cardiovascular Imaging. 2018;11(8):1109–18. DOI: 10.1016/j.jcmg.2018.03.003

13. Díaz‐Antón B, Madurga R, Zorita B, Wasniewski S, Moreno‐Arciniegas A, López‐Melgar B et al. Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters. ESC Heart Failure. 2022;9(2):1127–37. DOI: 10.1002/ehf2.13782

14. Omland T, Heck SL, Gulati G. The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2022;4(1):19–37. DOI: 10.1016/j.jaccao.2022.01.101